Drug
Paliperidone clinical trials
Also written Invega, Invega Sustenna and JNS010.
- studies test it
- 134
- open now
- 5
- in phase 3
- 51
- first study started
- 2003
Keep track of what changes. Save the paliperidone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
134 studies that test it; most in 2007 (18)
| Year | Studies |
|---|---|
| 2003 | 4 |
| 2004 | 12 |
| 2005 | 7 |
| 2006 | 11 |
| 2007 | 18 |
| 2008 | 14 |
| 2009 | 11 |
| 2010 | 13 |
| 2011 | 6 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 8 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 24
- Phase 2
- 9
- Phase 3
- 51
- Phase 4
- 48
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 102 · Other 32
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (40) · Janssen Research & Development, LLC (14) · Janssen Pharmaceutical K.K. (7) · Janssen-Cilag International NV (6) · Janssen Korea, Ltd., Korea (5) · Xian-Janssen Pharmaceutical Ltd. (4) · Johnson & Johnson Taiwan Ltd (4) · Janssen Scientific Affairs, LLC (3)
Often tested with
Tested in the same studies.
Risperidone (14) · Aripiprazole (7) · Olanzapine (6) · Quetiapine (4) · Valproic Acid (3) · Amisulpride (2) · Haloperidol (2) · Perphenazine (2)
Studies
Open first, then newest update. How each study uses paliperidone is read from its arms, and is right about nine times in ten.
Testing it · 134
- "Extended" (Alternate Day) Antipsychotic DosingRecruitingPhase 4Centre for Addiction and Mental HealthNCT04478838Written as paliperidone
- A Bioequivalence Study of PP3M in Patients With SchizophreniaRecruitingNot applicableCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07493551Written as Paliperidone Palmitate Injection (3M)
- Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in SchizophreniaNot yet recruitingPhase 4Jiangsu Province Nanjing Brain HospitalNCT07075237Written as Paliperidone Palmitate Injection (PP1M)
- Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh StudyNot yet recruitingPhase 4Sher-E-Bangla Medical CollegeNCT07153835Written as Paliperidone extended-release (ER)
- Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology AnalysisNot yet recruitingPhase 4Consorcio Centro de Investigación Biomédica en Red (CIBER)NCT06060886Written as Paliperidone
- Substance Misuse To Psychosis for StimulantsCompletedPhase 2/3The University of Hong KongNCT03485417Written as Paliperidone
- Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With SchizophreniaCompletedNot applicableCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07268430Written as Paliperidone Palmitate Injection(PP1M)
- Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or RisperidoneCompletedPhase 1Janssen Research & Development, LLCNCT02634463Written as Paliperidone
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or SchizophreniformCompletedPhase 3Janssen Scientific Affairs, LLCNCT02431702Written as Oral Paliperidone ER
- A Study of Paliperidone Palmitate 6-Month FormulationCompletedPhase 3Janssen Research & Development, LLCNCT04072575Written as PP6M injection Dose 1
- A Study of Paliperidone Palmitate 6-Month FormulationCompletedPhase 3Janssen Research & Development, LLCNCT03345342Written as PP6M
- A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month FormulationCompletedPhase 3Janssen-Cilag Ltd.NCT02713282Written as Paliperidone palmitate 3 month formulation (PP3M)
- A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare FacilitiesCompletedPhase 4Janssen Research & Development, LLCNCT03713658Written as Paliperidone Palmitate 50 mg eq.
- An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaCompletedPhase 3Janssen-Cilag International NVNCT00460512Written as Paliperidone ER
- A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare SettingsCompletedPhase 4Janssen-Cilag International NVNCT04940039Written as Paliperidone Palmitate 50 mg eq.
- A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With SchizophreniaCompletedPhase 3Janssen Research & Development, LLCNCT01051531Written as Paliperidone palmitate
- A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute SchizophreniaCompletedPhase 4Janssen Research & Development, LLCNCT01527305Written as Paliperidone palmitate
- Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderCompletedPhase 1Luye Pharma Group Ltd.NCT05321602Written as LY03010 156 mg treatment group, deltoid
- Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode SchizophreniaCompletedPhase 4University of California, Los AngelesNCT01451736Written as paliperidone palmitate
- Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot StudyWithdrawnNot applicableUniversity of Maryland, BaltimoreNCT01584466Written as Paliperidone
See all 134 studies that test paliperidone →
Given in every arm · 2 — paliperidone is usual care beside what is tested
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic MedicationCompletedPhase 2Astellas Pharma Global Development, Inc.NCT03557931Written as paliperidone
- A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With SchizophreniaCompletedPhase 1Janssen Research & Development, LLCNCT01559272Written as Paliperidone IR (Period 1)
As the comparator · 5 — what is tested is compared with paliperidone
- Relative Bioavailability of LY03010 Compared to Listed DrugCompletedPhase 1Luye Pharma Group Ltd.NCT04922593Written as INVEGA SUSTENNA
- A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaCompletedPhase 3Alkermes, Inc.NCT03345979Written as Paliperidone Palmitate
- A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia PatientsCompletedPhase 1Luye Pharma Group Ltd.NCT03751488Written as Invega Sustenna 156 MG in 1 ML Prefilled Syringe
- Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating EfficacyCompletedPhase 4Northwell HealthNCT00330863Written as Paliperidone
- Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With SchizophreniaCompletedPhase 3H. Lundbeck A/SNCT01795547Written as Paliperidone and paliperidone palmitate
Codes
What other systems call paliperidone · ClinicalTrials.gg INT006556
- MeSH (NLM) D000068882Paliperidone PalmitateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 838F01T721PALIPERIDONEConfirmed FDA, NLM, Wikidata
- RxNorm 679314Confirmed FDA, Wikidata
- Wikidata Q423292paliperidoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66293PaliperidoneOne source FDA
- DrugBank DB01267One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068882 | Paliperidone Palmitate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 838F01T721 | PALIPERIDONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 679314 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423292 | paliperidone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66293 | Paliperidone | One source FDA |
| DrugBank | DB01267 | — | One source Wikidata |
Also registered as paliperidone palmitate (UNII R8P8USM8FR · RxNorm 858045).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.